心血管-肾脏-肝脏-代谢综合征的治疗:贝特类药物再评价
综述再评价贝特类在心血管-肾脏-肝脏-代谢(CKLM)综合征中的作用,涉及糖尿病视网膜病变、肾病、神经病变、外周动脉疾病和代谢功能障碍相关脂肪性肝病。视网膜病变证据最强,非诺贝特减少视网膜病变进展和需激光治疗;肾病仅有事后分析提示白蛋白尿和eGFR下降获益,但可能致血肌酐可逆性升高;神经病变证据有限;肝脏获益中等。总体贝特类可能补充现有心代谢治疗,但需专门结局试验和更好分层后方可广泛临床实施。
要点
- 非诺贝特减少糖尿病视网膜病变进展和需视网膜激光治疗,证据最强。
- 事后分析提示非诺贝特对白蛋白尿进展和慢性eGFR下降有利,但贝特类可致血肌酐可逆性升高。
- 糖尿病神经病变证据有限;临床试验和真实世界研究提示可减少下肢截肢和糖尿病足并发症。
核心结论
- 贝特类可能通过靶向残余微血管和肝脏相关风险,补充当代心代谢治疗,但需专门结局试验和更好患者分层后方可更广泛临床实施。
研究设计与样本
- 本文为综述,再评价贝特类在CKLM综合征框架中的潜在作用,聚焦糖尿病视网膜病变、糖尿病肾病、糖尿病神经病变、外周动脉疾病和代谢功能障碍相关脂肪性肝病。
主要发现
- 糖尿病视网膜病变临床证据最强,非诺贝特减少视网膜病变进展和需视网膜激光治疗。
- 事后分析提示非诺贝特对白蛋白尿进展和慢性eGFR下降有利,但贝特类可致血肌酐可逆性升高。
- 糖尿病神经病变证据仍有限;临床试验和真实世界研究提示减少下肢截肢和糖尿病足并发症。
- 肝脏疾病中非诺贝特显示中等获益,选择性PPAR-α调节剂可能更有利影响肝酶、炎症和无创纤维化标志物。
关键数值与推荐
- 非诺贝特减少糖尿病视网膜病变进展和需视网膜激光治疗。
- 事后分析提示非诺贝特对白蛋白尿进展和慢性eGFR下降有利,但贝特类可致血肌酐可逆性升高。
- 临床试验和真实世界研究提示减少下肢截肢和糖尿病足并发症。
- 非诺贝特对肝脏疾病显示中等获益,选择性PPAR-α调节剂可能更有利影响肝酶、炎症和无创纤维化标志物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 糖尿病神经病变证据仍有限。
- 需要专门结局试验和更好患者分层后方可更广泛临床实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction-associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular-kidney-liver-metabolic (CKLM) syndrome. Although contemporary therapies such as sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and non-steroidal mineralocorticoid receptor antagonists (nsMRA) have improved cardiovascular and renal outcomes, diabetes-related microvascular complications remain common. Fibrates, traditionally used to lower triglycerides and increase high-density lipoprotein cholesterol, activate peroxisome proliferator-activated receptor-α (PPAR-α) and influence pathways involved in metabolic and vascular injury, including inflammation, oxidative stress, endothelial dysfunction, mitochondrial metabolism, lipid handling, fibrosis and angiogenesis. This review reappraises the potential role of fibrates within the CKLM syndrome framework, focusing on diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, peripheral artery disease and metabolic dysfunction-associated steatotic liver disease. Clinical evidence is the strongest for diabetic retinopathy, where fenofibrate reduces retinopathy progression and the need for retinal laser therapy. Post hoc analyses also suggest favourable effects on albuminuria progression and chronic estimated glomerular filtration rate (eGFR) decline, although fibrates may cause a reversible rise in serum creatinine. Evidence for diabetic neuropathy remains limited, while clinical trials and real-world studies suggest reductions in lower-extremity amputations and diabetic foot complications. In liver disease, fenofibrate has shown modest benefit, whereas selective PPAR-α modulators may more favourably influence liver enzymes, inflammation and non-invasive fibrosis markers. Overall, fibrates may complement contemporary cardiometabolic therapies by targeting residual microvascular and liver-related risk. However, dedicated outcome trials and improved patient stratification are needed before broader clinical implementation.
引用
- Diabetes, Obesity and Metabolism:Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。